NanoThea
Radiopharma nanoparticles · Oncology imaging & therapy
Overview
Radioactive polymer nanoparticles for cancer theranostics — PET imaging plus targeted radiotherapy in one platform.
What they do
NanoThea is the radiopharmaceutical arm of NanoGroup S.A., a Polish nanomedicine company listed on the Warsaw Stock Exchange (debuted on the GPW main market in December 2017). NanoGroup develops oncology and transplantology technologies through three subsidiaries: NanoVelos (anticancer drug nanoformulation), NanoSanguis (organ-preservation fluids) and NanoThea (diagnostic and theranostic nanoparticles). NanoThea's platform builds radioactive polymer nanoparticles designed to carry radioisotopes to tumour tissue.
Lead program & status
NanoThea's core technology attaches metal chelators to polymer nanoparticles, enabling labelling with a range of radioisotopes (such as gallium, copper or indium) for PET/SPECT imaging and, in the theranostic concept, pairing diagnostic imaging with targeted radiotherapy in a single carrier platform. The nanoparticles are designed to accumulate in tumour tissue via enhanced penetration and retention, with the carrier described as biocompatible and non-toxic. As of 2024 the programs are at a preclinical/development stage; NanoGroup's 2023-2025 strategy targeted securing at least one project partnership and broadening its portfolio. Specific clinical results have not been reported.
Why it matters
Theranostic radiopharmaceuticals - imaging and treating with the same targeting vehicle - are among oncology's fastest-growing modalities. A polymer-nanoparticle carrier compatible with multiple isotopes could offer flexibility versus single-molecule radioligands, if validated in the clinic.
FAQ
- What is NanoThea?
- NanoThea is a subsidiary of Warsaw-listed NanoGroup S.A. developing radioactive polymer nanoparticles for cancer theranostics - combined PET imaging and targeted radiotherapy.
- How does the theranostic platform work?
- Polymer nanoparticles are fitted with chelators so they can be labelled with diagnostic or therapeutic radioisotopes and directed to tumour tissue.
- What stage is NanoThea at?
- As of 2024 the technology is at a preclinical/development stage within NanoGroup, with no clinical results publicly reported.
Technology
NanoThea works in Radioligand Therapy (RLT) — A targeting molecule that delivers a radioactive payload to kill tumors from within.
Read the Radioligand Therapy (RLT) brief →Related companies
Company website / source ↗ Open the interactive map →
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.